Search our Database of Scientific Publications and Authors

I’m looking for a

    4719 results match your criteria Bullous Pemphigoid

    1 OF 95

    The cutaneous disease of Saint Ubald of Gubbio (1084-1160).
    J Eur Acad Dermatol Venereol 2017 May 23. Epub 2017 May 23.
    Gubbio and Gualdo Tadino General Hospital, Italy.
    Ubald was a Catholic Church Saint (1084 - 1160), born in Gubbio (Umbria, Italy) and died after two years of painful illness; his mummy is now guarded in a glass sarcophagus at Sant'Ubald Cathedral in Gubbio. Informations about Ubald are derived by his two main biographers: Iordanus (Giordano) of Città di Castello(1) and Theobaldus (Teobaldo), his successor in the episcopal seat(2) . This article is protected by copyright. Read More

    Association Between Inflammatory Skin Disease and Cardiovascular and Cerebrovascular Co-Morbidities in US Adults: Analysis of Nationwide Inpatient Sample Data.
    Am J Clin Dermatol 2017 May 22. Epub 2017 May 22.
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Suite 1600, 676 N. St. Clair St., Chicago, IL, 60611, USA.
    Background: Psoriasis, atopic dermatitis or eczema (AD-E), pemphigus, bullous pemphigoid (BP), and hidradenitis are chronic inflammatory skin disorders associated with systemic immune activation, considerable symptom burden, stigma, functional disturbances, and mental health symptoms. All of these might increase cardiovascular risk.

    Objective: The objective of this study was to determine whether these inflammatory skin diseases are associated with increased cardiovascular/cerebrovascular risk and/or disease. Read More

    [A particular type of cicatricial Pemphigoid with unique IgA deposit].
    Pan Afr Med J 2017 13;26:136. Epub 2017 Mar 13.
    Université de Sousse, Tunisie.
    Cicatricial Pemphigoid is a subepithelial bullous dermatosis which essentially involves the mucous membranes with cicatricial evolution We report the case of a 66-year old patient hospitalized with erosive gingivitis associated with dysphagia, dyspnea and blurred vision. Dermatologic examination showed erosive lesions involving the palate and the pharynx. Ophthalmologic examination showed symblepharons, ectropion and bilateral cataract. Read More

    [BULLOUS PEMPHIGOID RESISTANT TO CORTICOSTEROIDS].
    Harefuah 2016 Oct;155(10):593-595
    Department of Dermatology, Ha'Emek Medical Center, Afula, Israel.
    Introduction: Bullous pemphigoid is the most common autoimmune bullous disease, treated with low dosage local or systemic corticosteroids. This is a case report of a 65 years-old female patient with a month long history of a bullous disease before admission to the dermatology department with a generalized bullous rash. Clinical examination and histopathology revealed bullous pemphigoid. Read More

    Bullous Pemphigoid associated with Dipeptidyl Peptidase-4 Inhibitors: A Report of Five Cases.
    J Diabetes Investig 2017 May 18. Epub 2017 May 18.
    Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine.
    Bullous pemphigoid (BP) is an autoimmune blistering skin disorder. Recently, BP induced by dipeptidyl peptidase-4 (DPP-4) inhibitors has been a concern. Although DPP-4 inhibitors are commonly used in the Asian population due to their safety and efficacy, BP associated with DPP-4 inhibitors is sometimes seen in clinical settings. Read More

    Membranous glomerulonephropathy in a patient with bullous pemphigoid.
    CEN Case Rep 2017 May 4;6(1):50-54. Epub 2016 Nov 4.
    Division of Nephrology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
    Bullous pemphigoid (BP) is a common autoimmune blistering disease that can be complicated by autoimmune disorders. We describe a patient with BP who developed membranous glomerulonephropathy (MN). Proteinuria decreased during the clinical course as anti-BP180 antibody titers decreased. Read More

    Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin.
    Clin Exp Dermatol 2017 May 15. Epub 2017 May 15.
    Center for Blistering Diseases, Department of Dermatology, Tufts University School of Medicine, Boston, MA, USA.
    A 41-year-old white man was treated for bullous pemphigoid (BP) for 4 years, using high-dose prednisone as well as ciclosporin and mycophenolate mofetil. Sustained clinical improvement was not observed. He suffered several serious side effects. Read More

    Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid.
    Exp Dermatol 2017 May 13. Epub 2017 May 13.
    Department of Dermatology, University of Lübeck, Germany.
    Experimental models of bullous pemphigoid (BP), the most frequent subepidermal autoimmune bullous disease, revealed that the immune response leading to blister formation represents an incompletely understood complex process involving different inflammatory cells. In contrast to previous reports commonly focusing on limited molecular and cellular phenotypes of the disease, the aim of this study was to investigate a broad spectrum of markers of cellular immune activation in patients with BP. We found that serum levels of soluble CD4, myeloperoxidase, S100A12, eosinophil cationic protein, and soluble P-selectin were significantly elevated in patients with active BP compared with normal controls. Read More

    Eosinophils in Autoimmune Diseases.
    Front Immunol 2017 27;8:484. Epub 2017 Apr 27.
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    Eosinophils are multifunctional granulocytes that contribute to initiation and modulation of inflammation. Their role in asthma and parasitic infections has long been recognized. Growing evidence now reveals a role for eosinophils in autoimmune diseases. Read More

    An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.
    Br J Dermatol 2017 May 11. Epub 2017 May 11.
    Department of Dermatology, University of Lübeck, Lübeck, Germany.
    Background: Current treatment of bullous pemphigoid (BP) is based on the long-term use of topical and/or systemic corticosteroids associated with a high rate of adverse events and increased mortality.

    Objective: To study the corticosteroid-sparing potential of azathioprine and dapsone.

    Method: A prospective, multicenter, randomized, non-blinded clinical trial that compares efficacy and safety of two parallel groups of BP patients treated with oral methylprednisolone 0. Read More

    Bullous hemorrhagic dermatosis due to enoxaparin use in a bullous pemphigoid patient.
    Asia Pac Allergy 2017 Apr 26;7(2):97-101. Epub 2017 Apr 26.
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.
    Adverse reactions of subcutaneous low molecular weight heparin or unfractionated heparin could be complications by bleeding, heparin-induced thrombocytopenia, drug-induced liver injury, osteoporosis, and cutaneous reactions. Heparin-induced skin lesions vary from allergic reactions like erythema, urticaria, eczema to intradermal microvascular thrombosis associated with heparin-induced thrombocytopenia. There is a rare cutaneous complication, called bullous hemorrhagic dermatosis. Read More

    Multimorbidity in Bullous Pemphigoid: a case-control analysis of BP patients with age and gender matched controls.
    J Eur Acad Dermatol Venereol 2017 May 9. Epub 2017 May 9.
    Department of Dermatology, Singapore General Hospital, Singapore.
    Background: Bullous Pemphigoid (BP) is the most common autoimmune blistering disease in the elderly and is associated with increased mortality. The extent of multimorbidity in patients with BP and its impact on survival is unclear.

    Objectives: To describe the extent and spectrum of multimorbidity in patients with BP and to ascertain its impact on survival. Read More

    Immunofluorescence of Autoimmune Bullous Diseases.
    Surg Pathol Clin 2017 Jun 30;10(2):505-512. Epub 2017 Mar 30.
    Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
    Autoimmmune bullous diseases of skin and mucosa are uncommon, disabling, and potentially lethal diseases. For a quick and reliable diagnosis immunofluorescence is essential. This article describes two variants of immunofluorescence. Read More

    Increased Risk of Bullous Pemphigoid after First-Ever Stroke: A Population-Based Study.
    Neurodegener Dis 2017 May 4;17(4-5):166-170. Epub 2017 May 4.
    Department of Neurology, Sijhih Cathay General Hospital, New Taipei City, Taiwan, ROC.
    Background: We hypothesize that autoantibodies are induced after the blood-brain barrier is damaged by stroke and the risk of bullous pemphigoid (BP) is increased after stroke. We assess the risk of BP after first-ever stroke in a nationwide population-based cohort of first-ever stroke patients.

    Methods: We extracted data from the Longitudinal Health Insurance Database 2005 and identified patients with first-ever stroke as well as control patients matched for age, gender, and year of enrollment. Read More

    Successful Management of Acquired Hemophilia A Associated with Bullous Pemphigoid: A Case Report and Review of the Literature.
    Case Rep Hematol 2017 28;2017:2057019. Epub 2017 Mar 28.
    Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Background. Acquired hemophilia A (AHA) is a rare condition, due to the spontaneous formation of neutralizing antibodies against endogenous factor VIII. About half the cases are associated with pregnancy, postpartum, autoimmune diseases, malignancies, or adverse drug reactions. Read More

    [Sudden-onset bullous pemphigoid in a 12-year-old child].
    Arch Pediatr 2017 Jun 17;24(6):561-563. Epub 2017 Apr 17.
    Service de dermatologie et de vénéréologie, CHU Ibn Sina, Rabat, Maroc.
    Bullous pemphigoid (BP) is an acquired autoimmune disease that mainly affects the elderly. It is very rare in children. We report a sudden polymorphic case of BP in a 12-year-old child. Read More

    Complement-independent blistering mechanisms in bullous pemphigoid.
    Exp Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Department of Dermatology, Hokkaido University Graduate School of Medicine.
    Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease that clinically demonstrates tense blisters with widespread erythema, histologically demonstrates subepidermal blistering and immunologically demonstrates the presence of circulating autoantibodies against hemidesmosomal molecules. Complement activation has long been regarded as necessary for the generation of the BP. However, certain evidence has recently come to support non-complemental blistering mechanisms. Read More

    A distinct cutaneous microbiota pofile in autoimmune bullous disease patients.
    Exp Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.
    Bullous Pemphigoid (BP) is the most common autoimmune blistering disease in Europe. As both the incidence of the disease and the relative proportion of the elderly population continue to rise, it represents a significant medical burden. Whereas some progress has been achieved in defining genetic risk factors for autoimmune blistering diseases, no environmental agent has been conclusively identified. Read More

    Oesophageal involvement in 26 consecutive patients with mucous membrane pemphigoid.
    Br J Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France.
    Background: Oesophageal involvement of mucous membrane pemphigoid (MMP) has not yet been thoroughly described.

    Objectives: This study was undertaken to systematically characterise the endoscopic lesions of a series of patients with oesophageal symptoms seen in a referral centre for autoimmune bullous diseases.

    Methods: Clinical, endoscopic and immunological findings of consecutively referred MMP patients with oesophageal involvement, systemic and endoscopic treatments and follow-up, are described. Read More

    Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.
    Case Rep Dermatol 2017 Jan-Apr;9(1):38-44. Epub 2017 Feb 10.
    Akdeniz University Faculty of Medicine, Dermatology and Venereology Department, Antalya, Turkey.
    Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. Read More

    A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
    Health Technol Assess 2017 Mar;21(10):1-90
    Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
    Background: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with increased morbidity and mortality in the elderly.

    Objectives: To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP treatment with oral doxycycline or oral prednisolone. We hypothesised that starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral prednisolone. Read More

    Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.
    J Invest Dermatol 2017 Jun 5;137(6):1199-1203. Epub 2017 Apr 5.
    Institute of Anatomy and Cell Biology, Ludwig-Maximilians-Universität, Munich, Germany.
    Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Dermatology in Lübeck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents dedicating their work to autoimmune blistering diseases. Read More

    Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients.
    Photodiagnosis Photodyn Ther 2017 Mar 31. Epub 2017 Mar 31.
    Department of Dermatology, University of Alabama at Birmingham, United States. Electronic address:
    Treating skin cancers and extensive actinic keratosis in patients with bullous pemphigoid (BP) can be challenging. Treatment options pose unique risks in these patients as surgical wounds can have delayed wound healing and photodynamic therapy (PDT) may exacerbate their blistering disease. We report the successful use of PDT to treat actinic keratosis and skin cancers in two patients with BP, both of whom had excellent response to PDT and tolerated treatment without any bullous disease flares. Read More

    Amino acid duplication in the coiled-coil structure of collagen XVII alters its maturation and trimerization causing mild junctional epidermolysis bullosa.
    Hum Mol Genet 2017 Feb;26(3):479-488
    Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany.
    The function and stability of collagens depend on the accurate triple helix formation of three distinct polypeptide chains. Disruption of this triple-helical structure can result in connective-tissue disorders. Triple helix formation is thought to depend on three-stranded coiled-coil oligomerization sites within non-collagenous domains. Read More

    Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone.
    Am J Case Rep 2017 Mar 29;18:317-319. Epub 2017 Mar 29.
    NEUROFARBA Department, University of Florence and AOU Meyer, Florence, Italy.
    BACKGROUND Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs. CASE REPORT We describe the clinical case of an 11-year-old girl with SLE. Read More

    TWEAK/Fn14 activation contributes to the pathogenesis of bullous pemphigoid.
    J Invest Dermatol 2017 Mar 25. Epub 2017 Mar 25.
    Department of Dermatology, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China. Electronic address:
    Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) participates in various cellular effects by engaging its receptor of fibroblast growth factor inducible 14 (Fn14). Increased levels of soluble TWEAK are associated with systemic autoimmunity in patients with lupus erythematosus, rheumatoid arthritis or dermatomyositis. However, the role of TWEAK in bullous pemphigoid (BP) remains unknown. Read More

    Case of bullous pemphigoid coexisting with anti-desmoglein autoantibodies.
    J Dermatol 2017 Mar 24. Epub 2017 Mar 24.
    Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan.
    A 79-year-old Japanese woman had clinical and histopathological features of bullous pemphigoid, while direct immunofluorescence test revealed C3 and immunoglobulin G depositions in the lower cell surfaces of the epidermis in addition to those in the dermoepidermal junction. Chemiluminescent enzyme immunoassays were positive for desmoglein-1 and -3 antibodies in addition to anti-BP180 antibodies. In an immunoblotting study, antibodies against both 180-kDa bullous pemphigoid antigen and 130-kDa pemphigus vulgaris antigen were detected. Read More

    Human Orf complicated by Epidermolysis Bullosa Acquisita.
    Br J Dermatol 2017 Mar 24. Epub 2017 Mar 24.
    Dermatology Department, Saint-Louis Hospital, Paris, France.
    Orf is a DNA parapoxvirus transmitted to humans by contact with infected goats and sheep. Many complications have been reported after Orf infection including erythema multiforme. A few cases of auto-immune bullous dermatosis complicating Orf disease have been reported to date, usually characterized by tense blisters eruptions with or without mucosal involvement, linear deposition of C3, IgG and/or IgA along the basement membrane and negativity of indirect immunofluorescence analysis and ELISA assays (performed in 4 of 11 reported cases) against target antigens of bullous pemphigoid, mucous membrane pemphigoid or epidermolysis bullosa acquisita, except one case of mucosal pemphigoid with antilaminin-332 antibodies. Read More

    Skin disorders in Parkinson's disease: potential biomarkers and risk factors.
    Clin Cosmet Investig Dermatol 2017 9;10:87-92. Epub 2017 Mar 9.
    Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
    Parkinson's disease (PD) is one of the most common neurodegenerative disorders, characterized by a symptom triad comprising resting tremor, rigidity, and akinesia. In addition, non-motor symptoms of PD are well recognized and often precede the overt motor manifestations. Cutaneous manifestations as markers of PD have long been discussed, and cumulative evidence shows an increased prevalence of certain dermatological disorders in PD. Read More

    Bullous pemphigoid of infancy - report and review of infantile and pediatric bullous pemphigoid.
    Dermatol Online J 2017 Feb 16;23(2). Epub 2017 Feb 16.
    Department of Dermatology, Coimbra Hospital and University Centre, Coimbra, Portugal.
    A 4-month-old infant was observed with an acute itchy bullous dermatosis, predominantly involving the extremities, which revealed a dermal infiltrate rich in eosinophils, C3 deposits at the dermalepidermal junction, and circulating antibodies to BP180 antigen, confirming the diagnosis of bullous pemphigoid. He was initially treated with deflazacort 1 mg/kg/day, further increased to 2 mg/ kg/day, followed by reduction over seven weeks with complete clinical resolution within this period. We discuss epidemiology, etiology, relationship with vaccination, clinical features, and treatment of thisrelatively rare bullous dermatosis in the pediatric age. Read More

    Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.
    Arch Dermatol Res 2017 Mar 19. Epub 2017 Mar 19.
    Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, 100730, China.
    Bullous pemphigoid (BP) is a chronic debilitating autoimmune blistering disease that frequently occurs in the elderly population. Previous studies have suggested a high morbidity and mortality associated with BP. However, relatively few studies have investigated prognostic factors of BP mortality, and they showed considerably various results. Read More

    Bullous pemphigoid.
    Autoimmun Rev 2017 May 8;16(5):445-455. Epub 2017 Mar 8.
    Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany; Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
    Bullous pemphigoid (BP) is the most common autoimmune bullous disorder which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. Collagen XVII and dystonin-e have been identified as target antigens. BP affects mostly the elderly. Read More

    Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.
    Lancet 2017 Apr 6;389(10079):1630-1638. Epub 2017 Mar 6.
    Medical Research Council Clinical Trials Unit at University College London, London, UK.
    Background: Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.

    Methods: We did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Read More

    Dysregulation of mCD46 and sCD46 contribute to the pathogenesis of bullous pemphigoid.
    Sci Rep 2017 Dec 10;7(1):145. Epub 2017 Mar 10.
    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
    Bullous pemphigoid (BP) is an autoimmune bullous disease caused by autoantibodies against BP180 in the epidermal basement membrane. Autoantibody-mediated complement activation is an important process in BP pathogenesis. CD46, a crucial complement regulatory protein in the complement activation, has been reported to be involved in several autoimmune diseases. Read More

    Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita.
    Exp Dermatol 2017 Mar 7. Epub 2017 Mar 7.
    Lübeck Institute of Experimental Dermatology and Department of Dermatology, University of Lübeck, Lübeck, Germany.
    Pemphigoid diseases (PDs) are chronic and life-threatening autoimmune diseases of the skin and mucous membranes. PDs are characterized and caused by autoantibodies targeting components of the basement membrane. In the PD epidermolysis bullosa acquisita (EBA), the target autoantigen is type VII collagen. Read More

    Autoantibodies of non-inflammatory bullous pemphigoid hardly deplete type XVII collagen of keratinocytes.
    Exp Dermatol 2017 Mar 7. Epub 2017 Mar 7.
    Department of Dermatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
    Type XVII collagen (COL17) and the non-collagenous 16A (NC16A) domain is regarded as the major pathogenic domains for bullous pemphigoid (BP). Some patients with BP have autoantibodies against parts of COL17 outside the NC16A domain (hereinafter the non-NC16A domain) and show less inflammatory manifestations. There were no significant differences in titres and IgG subclasses between NC16A-BP and non-NC16A-BP as determined by indirect immunofluorescent microscopy. Read More

    Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson's disease is more relevant to bullous pemphigoid.
    Postepy Dermatol Alergol 2017 Feb 7;34(1):42-46. Epub 2017 Feb 7.
    Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
    Introduction: Bullous pemphigoid (BP) is an autoimmune blistering dermatosis of the elderly with autoimmunity to hemidesmosomal proteins, BP180 and BP230, which are expressed also in neuronal tissue.

    Aim: The aim here was to retrospectively compare the prevalence of neurodegenerative disorders (ND), particularly Parkinson's disease (PD), unspecified conditions manifesting as dementia and stroke, in two groups of ethnic Poles, with BP and with psoriasis (Ps), in order to obtain data whether BP is more prone to coexist with ND than Ps in the elderly. Psoriasis was chosen in this comparative study as it was considered to be a paradigm of cutaneous disease with systemic manifestations. Read More

    Accuracy of molecular diagnostics in pemphigus and bullous pemphigoid: comparison of commercial and modified mosaic indirect immunofluorescence tests as well as enzyme-linked immunosorbent assays.
    Postepy Dermatol Alergol 2017 Feb 7;34(1):21-27. Epub 2017 Feb 7.
    Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
    Introduction: Pemphigus and bullous pemphigoid (BP) are identified by autoantibodies (abs) against desmoglein 1, 3 (DSG1/3) and BP180/BP230, respectively. A novel mosaic to indirect immunofluorescence (IIF) using purified BP180 recombinant proteins spotted on slide and transfected cells expressing BP230, DSG1, DSG3 is available. The commercial (IgG detection) and modified (IgG4 detection) mosaic for indirect immunofluorescence (IIFc - IIF commercial, IIFm - IIF modified) and IgG ELISAs were evaluated in pemphigus and bullous pemphigoid (BP) molecular diagnostics. Read More

    1 OF 95